Enguent Jean-Pierre 4

What Happened
Enguent Jean-Pierre, Vice President, R&DSS at SEALSQ Corp (LAES), exercised options and then sold shares. On 2026-07-06 he exercised/converted 15,000 shares at $0.01 (cost $150). The Form 4 also shows a 15,000-share derivative conversion reported at $0.00. On 2026-07-08 he sold 15,000 common shares in the open market for a weighted-average price of $2.82, generating proceeds of $42,267. The transactions were effected under a pre-established Rule 10b5-1 trading plan.

Key Details

• Transaction dates: Exercise/conversion reported 2026-07-06; open-market sale reported 2026-07-08.
• Prices and values: Exercise 15,000 @ $0.01 (total $150); Sale 15,000 @ $2.82 (weighted avg) ≈ $42,267. Sale prices ranged $2.73–$2.91.
• Transaction codes: M = exercise/conversion of derivative; S = sale.
• Footnotes: Both the exercise and the sale were made pursuant to a Rule 10b5-1 trading plan adopted October 13, 2025 (F1, F3). F2 notes the sale price is a weighted average and the filer will provide per-trade breakdown on request.
• Shares owned after the transactions: Not specified in the provided Form 4 excerpt.
• Filing timeliness: Reported on 2026-07-08 for a 2026-07-06 transaction — appears timely.

Context

• The sequence (exercise followed by an open-market sale under a 10b5-1 plan) is effectively a planned monetize of option-derived shares; this is commonly a pre-arranged sale rather than an ad hoc decision.
• For retail investors: purchases can signal direct insider accumulation; planned or routine sales under 10b5-1 are less informative about the insider’s current view of the company.